Safety considerations for cereblon-recruiting targeted protein degraders

HESI Global’s Targeted Protein Degrader Safety Committee is pleased to share a new publication in Nature Reviews Drug Discovery: “Safety considerations for cereblon-recruiting targeted protein degraders.”

Targeted protein degraders offer exciting potential for treating difficult disease targets, but they can also unintentionally degrade off-target cereblon neosubstrates, creating important safety concerns, including possible toxicity and teratogenic risk. This publication highlights the need for rigorous, consistent approaches to evaluating these risks.

The authors review key aspects of cereblon biology, explore safety considerations for CRBN-recruiting degraders, and suggest best practices for monitoring on-target and off-target degradation. This work supports safer, science-based development of innovative therapies and reflects HESI Global’s mission to collaboratively address global health challenges through cross-sector scientific engagement.

Read the full paper here: Garside et al., 2026. Safety considerations for cereblon-recruiting targeted protein degraders. Nature Reviews Drug Discovery. https://rdcu.be/femcA

Learn more about the Targeted Protein Degrader Safety Committee here: https://hesiglobal.org/targeted-protein-degrader-safety/